GlassScriptPhysician profile
Jana Revels
NPI 1336791425
$2,737.70
in general payments reported to CMS, 2019-2025
11 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $47.33 · 2022: $310 · 2023: $450 · 2024: $512 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982 · Travel and Lodging: $398.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.22 |
| Travel and Lodging | $397.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $986.73 | 2023-2025 | Impella |
| Amgen INC. | $419.01 | 2023-2025 | Repatha, Repatha |
| Medtronic, INC. | $367.20 | 2022-2024 | Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $260.63 | 2023-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $183.82 | 2021-2025 | Camzyos |
| Boston Scientific Corporation | $112.53 | 2022-2025 | General - Pain Management |
| Astrazeneca Pharmaceuticals LP | $107.57 | 2022-2025 | Wainua, Andexxa, Farxiga |
| Shockwave Medical, INC | $105.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $81.50 | 2023-2025 | |
| Bracco Diagnostics INC. | $77.57 | 2024 | |
| Merck Sharp & Dohme LLC | $35.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jana Revels listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.